Next Article in Journal
Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma
Previous Article in Journal
Targeting the ATR-CHK1 Axis in Cancer Therapy
Previous Article in Special Issue
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Cancers 2017, 9(5), 42; doi:10.3390/cancers9050042

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

1
Vetsuisse Faculty, Institute of Animal Pathology, University of Bern, Länggassstrasse 122, 3012 Bern, Switzerland
2
MAP Kinase Resource, Bioinformatics, Melchiorstrasse 9, 3027 Bern, Switzerland
3
Proteomics Centre, Institute of Biochemistry, Vilnius University, Sauletekio al. 7, LT-10257 Vilnius, Lithuania
4
Faculty of Mathematics and Informatics, Vilnius University, Naugarduko st. 24, LT-03225 Vilnius, Lithuania
5
Ministry of Education and Science, A. Volano g. 2, LT-01516 Vilnius, Lithuania
6
Energy and Biotechnology Engineering Institute, Aleksandro Stulginskio University, Studentų g. 11, LT-53361 Akademija, Lithuania
7
Division of Human Genome Research Centre, Institute of Biosciences, Life Sciences Center, Vilnius University, Sauletekio al. 7, LT-10257 Vilnius, Lithuania
8
International School of Law and Business, Laisvss pr. 58, LT-05120 Vilnius, Lithuania
*
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Received: 22 March 2017 / Revised: 24 April 2017 / Accepted: 25 April 2017 / Published: 28 April 2017
(This article belongs to the Special Issue Small GTPases in Cancer)
View Full-Text   |   Download PDF [452 KB, uploaded 28 April 2017]   |  

Abstract

Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15–20% of patients are candidates for it at the diagnosis of disease. On the other hand, survival in patients, who undergo surgery, is less than 30%. In most cancers, genome stability is disturbed and pancreatic cancer is not the exception. Approximately 97% of pancreatic cancers have gene derangements, defined by point mutations, amplifications, deletions, translocations, and inversions. This review describes the most frequent genetic alterations found in pancreatic cancer. View Full-Text
Keywords: KRAS; TP53; CDKN2A; SMAD4; BRCA1; BRCA2; mutation; pancreatic cancer; genetic variant KRAS; TP53; CDKN2A; SMAD4; BRCA1; BRCA2; mutation; pancreatic cancer; genetic variant
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cicenas, J.; Kvederaviciute, K.; Meskinyte, I.; Meskinyte-Kausiliene, E.; Skeberdyte, A.; Cicenas, J. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers 2017, 9, 42.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top